Evaluation of public health interventions for anthrax: A report to the Secretary's Council on Public Health Preparedness

Biosecurity and Bioterrorism

Volumn 3, Issue 4, 2005, Pages 348-356

  Wein, Lawrence M ^a   Craft, David L ^b  

^a STANFORD UNIVERSITY   (United States)

^b WILLIAMS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIINFECTIVE AGENT;

ANTHRAX; ARTICLE; BIOLOGICAL MODEL; BIOLOGICAL WARFARE; COMPARATIVE STUDY; DISASTER PLANNING; DISEASE COURSE; EPIDEMIC; HUMAN; MASS IMMUNIZATION; PROBABILITY; PUBLIC HEALTH SERVICE; THEORETICAL MODEL; TIME;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BIOTERRORISM; DISASTER PLANNING; DISEASE OUTBREAKS; DISEASE PROGRESSION; HUMANS; MASS IMMUNIZATION; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PROBABILITY; PUBLIC HEALTH PRACTICE; TIME FACTORS;

EID: 33644984076     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2005.3.348     Document Type: Article

References (21)

1. Baccam S, Boechler M. Analysis of public health policies: evaluation of impact on anthrax casualties. Baton Rouge, LA: Innovative Emergency Management, Inc.; 2004.
2. Wein LM, Craft DL, Kaplan EH. Emergency response to an anthrax attack. Proc Natl Acad Sci USA 2003;100: 4346-4351.
3. Craft DL, Wein LM, Wilkins AH. Analyzing bioterror response logistics: the case of anthrax. Manage Sci 2004; 51:679-694.
4. Glassman HN. Discussion. Bacteriol Rev 1966;30:657-659.
5. Webb GF, Blaser MJ. Mailborne transmission of anthrax: Modeling and implications. Proc Natl Acad Sci USA 2002; 99:7027-7032.
6. Griffith KS, Mead P, Armstrong GL, et al. Bioterrorism-related inhalational anthrax in an elderly woman, Connecticut, 2001. Emerg Infect Dis 2003;9:681-688.
7. Brookmeyer R, Blades N, Hugh-Jones M, Henderson DA. The statistical analysis of truncated data: application to the Sverdlovsk anthrax outbreak. Biostatistics 2001;2: 233-247.
8. Williams JL, Noviello SS, Griffith KS, et al. Anthrax post-exposure prophylaxis in postal workers, Connecticut, 2001. Emerg Infect Dis 2002;8:1133-1137.
9. Jefferds MD, Laserson K, Fry AM, et al. Adherence to antimicrobial inhalational anthrax prophlyaxis among postal workers, Washington, D.C., 2001. Emerg Infect Dis 2002;8:1138-1144.
10. Brookmeyer R, Johnson E, Bollinger R. Public health vaccination policies for containing an anthrax outbreak. Nature 2004;432:901-904.
11. Wein LM, Liu Y, Leighton T. Evaluation of a HEPA-vaccine plan for indoor remediation after an airborne anthrax attack. Emerg Infect Dis 2005;11:69-76.
12. Brook I, Elliott TB, Pryor HI, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents 2001;18:559-562.
13. Grabenstein JD. Anthrax vaccine: a review. Immunol Allergy Clin North Am 2003;23:713-730.
14. Pittman PR, Kim-Ahn G, Pifat DY, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002;20: 1412-1420.
15. Fowler RA, Sanders GD, Bravata DM, et al. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax. Ann Intern Med 2005;1442:601-610.
16. Danzig R. Catastrophic Bioterrorism-What Is To Be Done? Washington, DC: Center for Technology and National Security Policy, National Defense University; August 2003.
17. Henderson DA. The looming threat of bioterrorism. Science 1999;283:1279-1282.
18. Webb GF. Being prepared: modeling the response to an anthrax attack. Ann Intern Med 2005;142:667-668.
19. Danzig R. Reload and the Post-attack Environment. Washington, DC: Center for Strategic and International Studies; September 2004.
20. Kaufman M. U.S. awards anthrax vaccine deal. Washington Post November 5, 2004:A4. Available at: www. washingtonpost.com/wp-dyn/articles/A26564-2004Nov4. html. Accessed September 21, 2005.
21. Brookmeyer R, Johnson E. Computer program to evaluate public health policy options in response to an anthrax outbreak: the impact of post exposure antibiotics and vaccine. Baltimore, Md: Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, January 23, 2004.